Advances made in CAR-T immunotherapy to prevent relapse in multiple myeloma
A team from Clínic-IDIBAPS has introduced a modification to a CAR-T immunotherapy for multiple myeloma that makes it more durable, according to resul1
A team from Clínic-IDIBAPS has introduced a modification to a CAR-T immunotherapy for multiple myeloma that makes it more durable, according to resul1
The Committee for the Evaluation of Medicinal Products for Human Use of the Spanish Agency of Medicines and Medical Devices (AEMPS) has approved ARI01
A study published recently in the journal Clinical Cancer Research identified biomarkers that can predict the response to CAR T-cell therapy targetin1
An international team, co-led by the Hospital Clínic-IDIBAPS, has identified four biomarkers that determine the risk of the recurrence of this cancer1
The ”la Caixa” Foundation will allocate 4.6 million euros to promoting research at the Hospital Clínic Barcelona, in order to develop new, personaliz1
IDIBAPS looks for talented professionals to meet the needs that appear periodically.
Enter